Scientists at the University of Houston (UH) have developed a new approach to glucose-sensing contact lenses by integrating an optical sensor. Though the correlation between glucose levels in tear samples and traditional blood samples is not yet established, the researchers said that their “smart” contact lens prototype demonstrates the versatility of their biosensing technology and a possible non-invasive alternative to existing glucose monitors.
FDA has approved Abbott’s Freestyle Libre Pro System for professional continuous glucose monitoring (CGM), which provides clinicians with 14 days’ worth of patient data so they can make more informed clinical decisions regarding diabetes management.
Boston Scientific has announced a $210 million deal to acquire EndoChoice Holdings, an Atlanta-based medtech specializing in endoscopic imaging systems, single-use devices, and infection control products.
BrainScope — a medtech specializing in traumatic brain injury (TBI) diagnostic technology that is backed by the U.S. Department of Defense (DOD)— has announced FDA clearance for Ahead 300, a hand-held medical device capable of objectively assessing the likelihood of TBI.
Scientists from the University of Texas in Arlington (UTA) have received a $440,670 National Institute of Health (NIH) grant for the continued development of a “closed-loop” blood pressure neurostimulation device for the cardiac care environment.
The National Institute of Health has awarded a $2.3 million grant to CivaTech, developer of an implantable device that provides targeted radiation treatment for cancer patients. CivaTech plans to use the grant to fund a clinical study that will evaluate safety and efficacy of the CivaSheet device in patients with pancreatic cancer.
FDA has published a draft guidance for industry outlining the agency’s approach to the coordinated development of antimicrobial drugs and antimicrobial susceptibility test (AST) devices. Though the agency wishes to better facilitate interactions between drug sponsors and device developers, FDA emphasized that applications will remain separate, and review timelines for separate products will not be influenced by each other.
Johnson & Johnson (J&J) subsidiary Acclarent announced that the FDA has awarded de novo approval to its balloon dilation system, the Aera System, which joins J&J’s portfolio of minimally invasive therapies for ear, nose, and throat (ENT) conditions. Aera is indicated for the treatment of persistent eustachian tube dysfunction (ETD).
Abbott has announced the sale of its medical optics business to Johnson & Johnson (J&J) in a deal worth $4.3 billion. Abbott continues to prepare for its acquisition of St. Jude later this year, and senior executives commented that the company is focused on building leadership positions in the cardiovascular device and diagnostic spaces.
Scientists from the University of Michigan (UM) have developed an implant that may one day act as an early warning system for metastatic tumors in lungs, liver, and brain caused by the spread of breast cancer.